Despite a reduction in the number of BM erythroblasts, EBI macrophages, and EBI, GM-CSF treatment did not contribute to development of an apparent peripheral blood anemia (Additional file 4: Figure S4A–D). This evidence concerns the gene CSF2 and anemia.